Risk Factors
431 articles
New Gene Inhibitor Drug for Patients with MTAP-Deleted Tumors
A new trial targets patients with advanced solid tumors, including pancreatic cancer, with an MTAP-deletion genetic mutation.
Newly Discovered Protein Complex in RAS Pathway May Provide a Treatment Target
Dr. Andrew Aguirre and other researchers from Dana-Farber and the Broad Institute are looking at the RAS pathway for a new target.
Could There Be a Cure in Vitamin C?
Vitamin C has been found to kill cancer cells that carry the KRAS mutation. This mutation is common in pancreatic and colorectal cancers.
Drug Onivyde Gives New Hope to Patients with Advanced Pancreatic Cancer
Onivyde (injectable irinotecan), combined with fluorouracil and leucovorin, has been approved as a second-line treatment for advanced pancreatic cancer.
Personalizing Pancreatic Cancer Treatment
Dr. Mark Ricigliano takes a closer look at the genetics of circulating tumor cells, to personalize pancreatic cancer treatment for the best results.
Patient-Focused Research to Better Understand Pancreatic Cancer
Dr. Diane Simeone stresses the importance of research and clinical trials to get better results for pancreatic cancer patients.